Adaptive Biotechnologies (NASDAQ:ADPT) Director Sells $748,201.60 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Robert Hershberg sold 30,664 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total transaction of $748,201.60. Following the sale, the director directly owned 46,683 shares in the company, valued at $1,139,065.20. This represents a 39.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $25.99 on Friday. The firm has a 50 day simple moving average of $22.06 and a 200-day simple moving average of $17.35. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The firm has a market cap of $4.15 billion, a PE ratio of -63.39 and a beta of 2.08. Adaptive Biotechnologies Corporation has a 1-year low of $12.00 and a 1-year high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business’s quarterly revenue was up 21.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.17) EPS. On average, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at $324,735,000. Ameriprise Financial Inc. raised its position in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the period. Wellington Management Group LLP boosted its holdings in Adaptive Biotechnologies by 53.2% in the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after acquiring an additional 2,053,944 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Finally, Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies during the fourth quarter valued at about $65,942,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ADPT. Morgan Stanley raised their price objective on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. dropped their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. BTIG Research raised their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Guggenheim lifted their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.